Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Down 84.8% in June

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 143,052 shares, a decline of 84.8% from the June 15th total of 942,551 shares. Approximately 12.1% of the company’s stock are short sold. Based on an average daily volume of 1,785,958 shares, the short-interest ratio is currently 0.1 days.

Regentis Biomaterials Stock Performance

Shares of RGNT stock traded up $0.15 during trading hours on Friday, hitting $3.79. 83,556 shares of the company were exchanged, compared to its average volume of 10,333,502. Regentis Biomaterials has a one year low of $1.23 and a one year high of $15.50. The firm has a 50-day moving average price of $2.97.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to its most recent filing with the SEC. The fund purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent quarter.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.